Showing 1021-1030 of 3153 results for "".
EHR User Series: Part I
https://practicaldermatology.com/topics/practice-management/ehr-user-series-part-i/22966/A Q&A series with users of EHR technology about their own experience and their broader impressions of EHR in dermatology.Content is the New Focal Point of Your SEO Strategy
https://practicaldermatology.com/topics/practice-management/content-is-the-new-focal-point-of-your-seo-strategy/22941/The goal of your dermatology website is to disseminate original, relevant and useful information that addresses readers' queries in a most satisfying manner.Dermatology Q&A: First Head-to-Head Data Highlight Safety and Efficacy of Biologics
https://practicaldermatology.com/topics/psoriasis/first-head-to-head-data-highlight-safety-and-efficacy-of-biologics/22032/A lead investigator on the first head-to-head trial of biologics shares insights on the future of biologic research and therapy.You Want to Start A New Practice: Now What?
https://practicaldermatology.com/topics/general-topics/PD0309_12-php/22866/After making the decision to start a practice, constructing a solid business plan and financial overview is critical.Conversations in Acne, Part 1
https://practicaldermatology.com/topics/acne-rosacea/conversations-in-acne-part-1/19867/As treatment options for acne expand, clinicians consider the potential to combine topical therapies or pair topicals with systemics, all while adhering to guidelines for care and prescribing antibiotics responsibly. In the first episode of this three-part series, host Neal Bhatia, MD speaks with HiDermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)Conversations in Acne, Part 2
https://practicaldermatology.com/topics/acne-rosacea/conversations-in-acne-part-2/19871/From isotretinoin to antibiotics—including next generation tetracyclines—the experts talk about key considerations for optimal outcomes, including the impact of diet. They also discuss management of trunk acne and strategies to reduce the risk for bacterial resistance. Host Neal Bhatia, MD leads theQuarantine Quorum: Circling the Wagons
https://practicaldermatology.com/topics/practice-management/quarantine-quorum-circling-the-wagons/18180/With Quarantine Quorum, host Neal Bahtia, MD provides a diary of life during the COVID-19 pandemic, talking to members of the dermatology community as they adapt to ongoing changes in their personal and private lives. In this edition, Hilary Baldwin, MD; Adam J. Friedman, MD; Mark Kaufmann, MD; and6 Tools That Can Benefit Every Dermatology Provider
https://practicaldermatology.com/topics/practice-management/6-tools-that-can-benefit-every-dermatology-provider/23283/Whether you’ve never heard of it or simply forgot about it, each of these tools can improve patient care in the clinic.• Cosmetic Eyeliner Tattoo Complications
• Morphea After Endovenous Cyanoacrylate Adhesive Embolizationhttps://practicaldermatology.com/youngmd-connect/resident-resource-center/bull-cosmetic-eyeliner-tattoo-complicationsbrbull-morphea-after-endovenous-cyanoacrylate-adhesive-embolization/23771/